Search for drugs:
Typing the drug name to query
TRASTUZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effects of trastuzumab on electrocardiographic (ECG) endpoints, including QTc interval duration, were evaluated in patients with HER2 positive solid tumors. Trastuzumab had no clinically relevant effect on the QTc interval duration and there was no apparent relationship between serum trastuzumab concentrations and change in QTcF interval duration in patients with HER2 positive solid tumors.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
30
24062
Other ADRs
71758
38309829
Odds Ratio = 0.666
Drug Property Information
ATC Code(s):
- L01XC03 - trastuzumab
- L01XC0 -
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- L01XY02 - trastuzumab
- L01XY - Combinations of antineoplastic agents
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- L01XC41 - trastuzumab
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- L01XC14 - trastuzumab
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:TRASTUZUMAB
Active Ingredient UNII:P188ANX8CK
Drugbank ID:DB00072
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection, powder, lyophilized, for solution; kit
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
1: Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
[Chen Daniel H,Tyebally Sara,Malloupas Michael,Roylance Rebecca,Spurrell Emma,Raja Fharat,Ghosh Arjun K]Curr Cardiol Rep,2021 Jan 26;23(3):16. PMID: 33501515
2: Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
[Goel Shom,Pernas Sonia,Tan-Wasielewski Zhenying,Barry William T,Bardia Aditya,Rees Rebecca,Andrews Chelsea,Tahara Rie Kawabori,Trippa Lorenzo,Mayer Erica L,Winer Eric P,Spring Laura M,Tolaney Sara M]Clin Breast Cancer,2019 Dec;19(6):399-404. PMID: 31235441
3: Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
[Jovenaux Ludovic,Cautela Jennifer,Resseguier Noemie,Pibarot Michele,Taouqi Myriam,Orabona Morgane,Pinto Johan,Peyrol Michael,Barraud Jeremie,Laine Marc,Bonello Laurent,Paganelli Franck,Barlesi Fabrice,Thuny Franck]Int J Cardiol,2017 Aug 15;241:387-392. PMID: 28365180
4: Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
[Brown S-A,Nhola L,Herrmann J]Clin Pharmacol Ther,2017 Jan;101(1):65-80. PMID: 27806435
5: Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
[Magdy Tarek,Burmeister Brian T,Burridge Paul W]Pharmacol Ther,2016 Dec;168:113-125. PMID: 27609196
6: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
[Chan Arlene,Delaloge Suzette,Holmes Frankie A,Moy Beverly,Iwata Hiroji,Harvey Vernon J,Robert Nicholas J,Silovski Tajana,Gokmen Erhan,von Minckwitz Gunter,Ejlertsen Bent,Chia Stephen K L,Mansi Janine,Barrios Carlos H,Gnant Michael,Buyse Marc,Gore Ira,Smith John,Harker Graydon,Masuda Norikazu,Petrakova Katarina,Zotano Angel Guerrero,Iannotti Nicholas,Rodriguez Gladys,Tassone Pierfrancesco,Wong Alvin,Bryce Richard,Ye Yining,Yao Bin,Martin Miguel,ExteNET Study Group]Lancet Oncol,2016 Mar;17(3):367-377. PMID: 26874901
7: Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
[Garg Amit,Li Jing,Clark Emma,Knott Adam,Carrothers Timothy J,Marier Jean-François,Cortés Javier,Brewster Michael,Visich Jennifer,Lum Bert]Cancer Chemother Pharmacol,2013 Nov;72(5):1133-41. PMID: 23999693
8: Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience.
[Dogan Erkan,Yorgun Hikmet,Petekkaya Ibrahim,Ozer Necla,Altundag Kadri,Ozisik Yavuz]Med Oncol,2012 Dec;29(5):3232-9. PMID: 22729366
9: Insights into cardiovascular side-effects of modern anticancer therapeutics.
[Stortecky Stefan,Suter Thomas M]Curr Opin Oncol,2010 Jul;22(4):312-7. PMID: 20535072
10: Antineoplastic chemotherapy induced QTc prolongation.
[Bagnes Claudia,Panchuk Patricia Natalia,Recondo Gonzalo]Curr Drug Saf,2010 Jan;5(1):93-6. PMID: 20210725
11: The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
[Youssef George,Links Matthew]Am J Cardiovasc Drugs,2005;5(4):233-43. PMID: 15984906
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.